| 抗体类型 | 单抗 | 同型对照： | Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), FITC |
| 浓度： | 5 µL/Test | 用法： | 5 μL (0.06 μg)/test (Flow) |
| 产品详细信息Description: This 4B4 (4B4-1) monoclonal antibody reacts with human CD137 (also known as 4-1BB or TNFRSF9), which is an inducible member of the TNFR family of costimulatory molecules expressed on T cells, natural killer cells, dendritic cells, granulocytes, and mast cells. Involved in recruiting TNFR-associated factors (TRAF) 1 and 2, CD137 signaling plays a role in T cell activation, maintaining the survival of activated and CD8 memory T cells, as well as suppressing myelopoiesis and dendriticcell development. Stimulation of this receptor has also been shown to promote expansion of CD4+CD25+ T regulatory cells i{ex vivoi}. The ligand for CD137, 4-1BBL, is found on activated macrophages, mature B cells, hematopoietic stem cells, and myeloid progenitor cells.Applications Reported: This 4B4 (4B4-1) antibody has been reported for use in flow cytometric analysis.Applications Tested: This 4B4 (4B4-1) antibody has been pre-titrated and tested by flow cytometric analysis on Con A-stimulated normal human peripheral blood cells. This can be used at 5 µL (0.06 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser.Filtration: 0.2 µm post-manufacturing filtered.靶标信息CD137, also known as TNFRSF9 or 4-1BB, is an inducible costimulatory molecule expressed mainly on activated T cells. Its ligand, known as 4-1BBL, is expressed on activated macrophages, mature B cells, hematopoietic stem cells, and myeloid progenitor cells. CD137 signaling leads to maintaining the survival of activated T cells and CD8+ memory T cells, and clonal expansion of T cells, but also to suppressing myelopoiesis and dendritic cell development. Triggered CD137 induces a cytokine release profile regulating peripheral monocyte survival. Soluble forms of CD137 may provide negative control mechanism for some immune responses. |
| 数据 |
| CD137 (4-1BB) Antibody (11-1379-42) in FlowStaining of ConA-stimulated human peripheral blood cells with Anti-Human CD69 APC (Product # 17-0699-42) and Mouse IgG1 kappa Isotype Control FITC (Product # 11-4714-42) (left) or Anti-Human CD137 (4-1BB) FITC (right). Total viable cells were used for analysis. |
| 推荐产品： |
| 二抗荧光二抗免疫组化一抗标签抗体 |
| 参考文献： |
| 1.Oxidative medicine and cellular longevityAntroquinonol Exerts Immunosuppressive Effect on CD8+T Cell Proliferation and Activation to Resist Depigmentation Induced by H2O2."Published figure using CD137 (4-1BB) monoclonal antibody (Product # 11-1379-42) in Flow Cytometry"2.OncotargetSurrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.3.Nature medicineA transcriptionally and functionally distinct PD-1+CD8+T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade."11-1379 was used in Flow cytometry/Cell sorting to compare transcriptional, metabolic and functional signatures of intratumoral CD8+ T lymphocyte populations with high, intermediate and no PD-1 expression from non-small-cell lung cancer patients."AuthorsThommen DS,Koelzer VH,Herzig P,Roller A,Trefny M,Dimeloe S,Kiialainen A,Hanhart J,Schill C,Hess C,Savic Prince S,Wiese M,Lardinois D,Ho PC,Klein C,Karanikas V,Mertz KD,Schumacher TN,Zippelius A4.OncotargetSurrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. |
QQ:1749072012